Topological virtual screening: a way to find new compounds active in ulcerative colitis by inhibiting NF-κB

María Gálvez-Llompart1, María C Recio, Ramón García-Domenech

  • 1Molecular Connectivity and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Avda. VA Estellés, s/n, 46100 Burjassot, Valencia, Spain.

Molecular Diversity
|July 1, 2011
PubMed

Insights

This study developed a computational model to identify new ulcerative colitis treatments by targeting Nuclear Factor Kappa B (NF-κB). The model successfully predicted 28 compounds for further testing, offering a promising avenue for inflammatory bowel disease research.

Area of Science:

  • Pharmacology
  • Computational Chemistry
  • Immunology

Background:

  • Ulcerative colitis and Crohn's disease are chronic gastrointestinal inflammatory conditions.
  • Nuclear Factor Kappa B (NF-κB) is a key regulator of inflammatory and immune gene expression.

Purpose of the Study:

  • To develop a predictive model for identifying novel compounds that inhibit NF-κB activity.
  • To discover new therapeutic agents for ulcerative colitis by targeting NF-κB.

Main Methods:

  • Topological Virtual Screening was employed using topological indices as structural descriptors.
  • Linear discriminant analysis was used to build a model relating structural features to biological activity.
  • A two-function discriminant model was constructed to differentiate NF-κB active/inactive and ulcerative colitis active/inactive compounds.

Main Results:

  • A topological model was successfully developed with two discriminant functions.
  • The model effectively discriminated between compounds based on NF-κB and ulcerative colitis activity.
  • Twenty-eight novel compounds were predicted to be active and selected for experimental validation.

Conclusions:

  • Topological Virtual Screening provides an effective computational approach for discovering new ulcerative colitis therapeutics.
  • The developed model shows potential for identifying drug candidates that inhibit NF-κB.
  • Further in vitro and in vivo studies are warranted for the 28 selected compounds.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...